GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » E10

Biomarin Pharmaceutical (Biomarin Pharmaceutical) E10

: $-1.11 (As of Dec. 2023)
View and export this data going back to 1999. Start your Free Trial

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.110. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.11 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 6.50% per year. During the past 5 years, the average E10 Growth Rate was 6.00% per year. During the past 10 years, the average E10 Growth Rate was -14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Biomarin Pharmaceutical was 20.60% per year. The lowest was -63.90% per year. And the median was 6.00% per year.

As of today (2024-04-19), Biomarin Pharmaceutical's current stock price is $90.08. Biomarin Pharmaceutical's E10 for the quarter that ended in Dec. 2023 was $-1.11. Biomarin Pharmaceutical's Shiller PE Ratio of today is .


Biomarin Pharmaceutical E10 Historical Data

The historical data trend for Biomarin Pharmaceutical's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.59 -1.36 -1.43 -1.32 -1.11

Biomarin Pharmaceutical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.32 -1.28 -1.24 -1.18 -1.11

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Shiller PE Ratio falls into.



Biomarin Pharmaceutical E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomarin Pharmaceutical's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.11/129.4194*129.4194
=0.110

Current CPI (Dec. 2023) = 129.4194.

Biomarin Pharmaceutical Quarterly Data

per share eps CPI Adj_EPS
201403 -0.270 99.695 -0.351
201406 -0.230 100.560 -0.296
201409 0.050 100.428 0.064
201412 -0.470 99.070 -0.614
201503 -0.430 99.621 -0.559
201506 -0.510 100.684 -0.656
201509 -0.600 100.392 -0.773
201512 0.390 99.792 0.506
201603 -0.510 100.470 -0.657
201606 -2.580 101.688 -3.284
201609 -0.220 101.861 -0.280
201612 -0.530 101.863 -0.673
201703 -0.090 102.862 -0.113
201706 -0.210 103.349 -0.263
201709 -0.070 104.136 -0.087
201712 -0.300 104.011 -0.373
201803 -0.260 105.290 -0.320
201806 -0.090 106.317 -0.110
201809 -7.000 106.507 -8.506
201812 -0.030 105.998 -0.037
201903 -0.320 107.251 -0.386
201906 -0.210 108.070 -0.251
201909 0.300 108.329 0.358
201912 0.080 108.420 0.095
202003 0.440 108.902 0.523
202006 -0.160 108.767 -0.190
202009 4.010 109.815 4.726
202012 0.120 109.897 0.141
202103 0.090 111.754 0.104
202106 0.070 114.631 0.079
202109 -0.200 115.734 -0.224
202112 -0.320 117.630 -0.352
202203 0.630 121.301 0.672
202206 0.150 125.017 0.155
202209 -0.040 125.227 -0.041
202212 -0.001 125.222 -0.001
202303 0.270 127.348 0.274
202306 0.290 128.729 0.292
202309 0.210 129.860 0.209
202312 0.110 129.419 0.110

Add all the adjusted EPS together and divide 10 will get our e10.


Biomarin Pharmaceutical  (NAS:BMRN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Biomarin Pharmaceutical E10 Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Executives
Jean Jacques Bienaime director, officer: Chief Executive Officer 925 PAGE MILL ROAD, PALO ALTO CA 94304
George Eric Davis officer: VP, General Counsel C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jeffrey Robert Ajer officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs officer: Chief Medical Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Charles Greg Guyer officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Erin Burkhart officer: GVP, Chief Accounting Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
V Bryan Lawlis director
Richard A Meier director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon director 770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612

Biomarin Pharmaceutical (Biomarin Pharmaceutical) Headlines

From GuruFocus